Correction: Bar-Sela et al. Cannabis Consumption Used by Cancer Patients during Immunotherapy Correlates with Poor Clinical Outcome. Cancers 2020, 12, 2447

Error in Table In the original article [1], there was a mistake in Table 1 as published. Typing errors were made regarding demographics and medical conditions data. The corrected Table 1 appears below. Table 1. Demographics and medical conditions. Characteristics Cannabis Non-Users N = 68 Cannabis Users N = 34 Age in years median (range) 69 (18–92) 66 (37–85) p-Value Gender—N (%) Female 22 (32.4) 10 (29.5) Male 46 (67.6) 24 (70.5) 0.9399 Performance Status Eastern Cooperative Oncology Group (ECOG)—N (%) 1≤ 55 (80.8) 24 (70.5) 0.3568 ≥2 13 (19.1) 10 (29.4) 0.3568 Chronic diseases per patient—N (%) 0 22 (32.3) 13 (22.0) 0.7124 1 16 (23.5) 7 (20.5) 0.9332 2 or more 30 (44.1) 14 (41.1) 0.9437 Background diseases—N (%) Chronic heart disease 18 (26.4) 5 (14.7) 0.2762 Diabetes 17 (25.0) 6 (17.6) 0.5576 High blood pressure 34 (50.0) 13 (34.1) 0.3612 Chronic obstructive pulmonary disease (COPD) 9 (13.2) 3 (8.8) 1 Hyperlipidemia 23 (33.8) 7 (20.5) 0.2491 Other 2 (2.9) 0 (0.0) 1 Type of malignancy—N (%) Non-small cell lung cancer 37 (54.4) 20 (58.8) 0.8325 Melanoma 25 (36.7) 9 (26.4) 0.414 Renal cell carcinoma 4 (5.8) 2 (5.8) 1 Other 2 (2.9) 3 (8.8) 1 Main site of metastasis—N (%) Brain 12 (17.6) 8 (13.2) 0.6593 Lungs 39 (57.3) 23 (67.6) 0.4303 Liver 13 (19.1) 11 (32.3) 0.2157 Table 1. Cont. Characteristics Cannabis Non-Users N = 68 Cannabis Users N = 34 p-Value Immunotherapy given as—N (%) First line of treatment 31 (45.5) 8 (23.5) 0.05178 Second line of treatment or more 37 (54.4) 26 (76.4) 0.05178 Checkpoint therapy—N (%) Anti PD1: Pembrolizumab or Nivolumab 47 (69.1) 29 (85.2) 0.127 Ipilimumab and Nivolumab 16 (23.5) 4 (11.7) 0.2517 Anti PDL-1: Durvalumab or Atezolizumab 5 (7.3) 1 (2.9) 1 The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. The original article has been updated.